Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 42
2023 40
2024 16

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 38723124

101 results

Results by year

Filters applied: . Clear all
Page 1
Selpercatinib (Retevmo): CADTH Reimbursement Recommendation: Indication: Adult patients with rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. PMID: 38723124 Free Books & Documents. Review.
Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. PMID: 38723134 Free Books & Documents. Review.
Lenvatinib (Lenvima) in Combination With Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. PMID: 38723120 Free Books & Documents. Review.
Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul. PMID: 38713782 Free Books & Documents. Review.
Asciminib (Scemblix): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with 2 or more tyrosine kinase inhibitors [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug. PMID: 38713779 Free Books & Documents. Review.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696640 Free Books & Documents. Review.
Pembrolizumab (Keytruda) in Combination With Lenvatinib (Lenvima): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696635 Free Books & Documents. Review.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: As monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non–small cell lung cancer whose tumours have programmed death-ligand 1 expression on 50% or more of tumour cells [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep. PMID: 38696634 Free Books & Documents. Review.
101 results
-